NO20026001L - 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider - Google Patents

3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider

Info

Publication number
NO20026001L
NO20026001L NO20026001A NO20026001A NO20026001L NO 20026001 L NO20026001 L NO 20026001L NO 20026001 A NO20026001 A NO 20026001A NO 20026001 A NO20026001 A NO 20026001A NO 20026001 L NO20026001 L NO 20026001L
Authority
NO
Norway
Prior art keywords
nucleosides
deoxy
promoters
beta
compositions
Prior art date
Application number
NO20026001A
Other languages
English (en)
Norwegian (no)
Other versions
NO20026001D0 (no
Inventor
Martin L Bryant
Gilles Gosselin
Jean Louis Imbach
Original Assignee
Univ Montpellier Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montpellier Ii filed Critical Univ Montpellier Ii
Publication of NO20026001D0 publication Critical patent/NO20026001D0/no
Publication of NO20026001L publication Critical patent/NO20026001L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20026001A 2000-06-15 2002-12-13 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider NO20026001L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21210000P 2000-06-15 2000-06-15
PCT/US2001/019147 WO2001096353A2 (en) 2000-06-15 2001-06-15 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES

Publications (2)

Publication Number Publication Date
NO20026001D0 NO20026001D0 (no) 2002-12-13
NO20026001L true NO20026001L (no) 2003-02-12

Family

ID=22789563

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026001A NO20026001L (no) 2000-06-15 2002-12-13 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider

Country Status (27)

Country Link
EP (1) EP1296995B1 (zh)
JP (1) JP4639032B2 (zh)
KR (2) KR20030032967A (zh)
CN (3) CN101012259A (zh)
AP (1) AP1771A (zh)
AR (1) AR035711A1 (zh)
AT (1) ATE411332T1 (zh)
AU (2) AU6692701A (zh)
BR (1) BR0111732A (zh)
CA (1) CA2413163C (zh)
CZ (1) CZ2003122A3 (zh)
DE (1) DE60136181D1 (zh)
EA (1) EA005774B1 (zh)
ES (1) ES2317912T3 (zh)
IL (3) IL153379A0 (zh)
MA (1) MA27126A1 (zh)
MX (1) MXPA02012443A (zh)
MY (1) MY141594A (zh)
NO (1) NO20026001L (zh)
NZ (2) NZ523632A (zh)
OA (1) OA12384A (zh)
PE (1) PE20020216A1 (zh)
PL (1) PL360404A1 (zh)
UY (1) UY26779A1 (zh)
WO (1) WO2001096353A2 (zh)
YU (1) YU94802A (zh)
ZA (2) ZA200300168B (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259068A1 (en) 2000-04-13 2001-10-30 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
JP5087211B2 (ja) 2002-06-28 2012-12-05 イデニクス（ケイマン）リミテツド フラビウィルス感染治療のための２′および３′−ヌクレオシドプロドラッグ
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR100855907B1 (ko) * 2002-09-13 2008-09-02 노파르티스 아게 내성 ＨＢＶ 균주 치료용 β-Ｌ-2'-데옥시뉴클레오시드 및병용 요법
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
EP1745573A4 (en) 2003-03-20 2010-05-26 Microbiol Quimica Farmaceutica PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
KR20060015542A (ko) 2003-04-28 2006-02-17 이데닉스 (케이만) 리미티드 산업 규모의 뉴클레오시드 합성
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
WO2005003374A2 (en) 2003-06-30 2005-01-13 Idenix (Cayman) Limited SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
WO2006138507A1 (en) 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
MX2010013678A (es) 2008-06-11 2011-02-24 Lasergen Inc Nucleotidos y nucleosidos y metodos para su uso en secuenciacion de adn.
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
CN102917585A (zh) 2010-04-01 2013-02-06 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308518B2 (en) 2011-09-13 2017-08-17 Agilent Technologies, Inc. 5-methoxy, 3'-oh unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
CN112384228A (zh) * 2018-04-12 2021-02-19 莫迪斯治疗公司 用于治疗由失衡的核苷酸池引起的疾病的脱氧核苷的前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
SE505648C2 (sv) * 1996-08-30 1997-09-22 Scania Cv Ab Anordning vid ett fordon för monterbar anfästning av en förarplatsmodul
CA2340156C (en) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b

Also Published As

Publication number Publication date
AR035711A1 (es) 2004-07-07
JP4639032B2 (ja) 2011-02-23
PE20020216A1 (es) 2002-04-16
KR20030032967A (ko) 2003-04-26
ZA200404306B (en) 2005-06-15
CA2413163C (en) 2008-11-18
PL360404A1 (en) 2004-09-06
AU2001266927B2 (en) 2006-12-14
DE60136181D1 (de) 2008-11-27
EP1296995A2 (en) 2003-04-02
OA12384A (en) 2006-04-17
IL178864A0 (en) 2007-03-08
ZA200300168B (en) 2004-07-07
NO20026001D0 (no) 2002-12-13
AP2003002713A0 (en) 2003-03-31
EA005774B1 (ru) 2005-06-30
IL153379A0 (en) 2003-07-06
CN1295242C (zh) 2007-01-17
ATE411332T1 (de) 2008-10-15
BR0111732A (pt) 2003-06-24
NZ535246A (en) 2006-06-30
AU6692701A (en) 2001-12-24
YU94802A (sh) 2006-03-03
MY141594A (en) 2010-05-14
AP1771A (en) 2007-08-23
MA27126A1 (fr) 2005-01-03
ES2317912T3 (es) 2009-05-01
KR20070048277A (ko) 2007-05-08
CA2413163A1 (en) 2001-12-20
EA200300023A1 (ru) 2003-08-28
WO2001096353A3 (en) 2002-04-18
EP1296995B1 (en) 2008-10-15
NZ523632A (en) 2005-03-24
MXPA02012443A (es) 2004-09-10
IL153379A (en) 2007-02-11
JP2004533403A (ja) 2004-11-04
CN101012259A (zh) 2007-08-08
CN1900104A (zh) 2007-01-24
CZ2003122A3 (cs) 2003-06-18
CN1452627A (zh) 2003-10-29
WO2001096353A2 (en) 2001-12-20
UY26779A1 (es) 2001-12-28

Similar Documents

Publication Publication Date Title
NO20026001L (no) 3&#39;-promedikamenter av 2&#39;-deoksy-&lt;Beta&gt;-L-nukleosider
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
PL330407A1 (en) Substituted cyclopentane compounds useful as neuraminidaze inhibitors
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
BR0009267A (pt) Tratamento da hepatite c com o uso da hipertermia
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2&#39;-ДЕЗОКСИНУКЛЕОЗИДОВ
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
EA200000836A1 (ru) Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
ATE376445T1 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid- analoge
BR0109716A (pt) Uso de um nucleosìdeo ou um análogo de nucleosìdeo no tratamento de infecção viral por hepatite delta
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
WO2002026249A3 (en) Methods for inhibition of viral infection
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
RS53223B (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
KR900005991A (ko) 옥트레오티드(Octreotide)를 함유한 약학적 조성물
UA37622A (uk) 1,5-піперидил - 3,7-біс/діетаноламіну/ - піримідил ізовалеріанат, що використовується для діагностики вірусних інфекцій